Indication: Non-Hodgkin's Lymphoma

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma

Relapsed/Refractory Aggressive

Sub-indication: DLBCL

Line of Therapy: second line

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Acerta Pharma BV

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.